Effective medical treatment for thyroid eye disease, a debilitating condition that can cause sight loss, has been lacking. A recent phase III trial of teprotumumab, an IGF1R antagonist, reports encouraging results and could be a game changer. Here, the trial is put in the context of current management strategies to address this question.

中文翻译：

---

照耀甲状腺眼病。

一直缺乏对甲状腺眼疾病的有效治疗，甲状腺疾病是一种会导致视力下降的虚弱症状。最近一项关于IGR1R拮抗剂teprotumumab的III期临床试验报告了令人鼓舞的结果，可能会改变游戏规则。在这里，将审判放在当前管理策略的背景下来解决这个问题。